Current disease status-First occurrence of the cancer Posts on Medivizor

Evaluating the effect of total neoadjuvant therapy versus standard neoadjuvant chemoradiotherapy and planned adjuvant chemotherapy on the survival of patients with locally advanced rectal cancer.

Posted by Medivizor on Sep 1, 2022 in Colorectal cancer | 0 comments

In a nutshell This study investigated the effect of total neoadjuvant therapy (TNT) versus standard neoadjuvant chemoradiotherapy (CRT) and planned adjuvant chemotherapy on the survival of patients with locally advanced rectal cancer (LARC). The data showed that TNT did not increase survival compared with standard CRT and planned adjuvant...

Adding pembrolizumab before and after surgery for early triple-negative breast cancer

Posted by Medivizor on Jun 30, 2022 in Breast cancer | 0 comments

In a nutshell This study aimed to investigate pembrolizumab (Keytruda) before and after surgery in patients with early triple-negative breast cancer (TNBC). This study concluded that the addition of pembrolizumab to chemotherapy before surgery and after surgery for TNBC improved the survival without complications from TNBC in these...

Is chemotherapy after surgery followed by atezolizumab a good treatment option in patients with early stage non-small-cell lung cancer?

Posted by Medivizor on Feb 7, 2022 in Lung cancer | 0 comments

In a nutshell The study aimed to investigate the effectiveness and safety of atezolizumab (Tecentriq) versus best supportive care after chemotherapy in patients with resected early-stage non-small-cell lung cancer (NSCLC). The study showed atezolizumab is effective and has better outcomes than best supportive in these...

Can osimertinib be used as first-line therapy in older patients with EGFR-mutated NSCLC?

Posted by Medivizor on Jan 30, 2022 in Lung cancer | 0 comments

In a nutshell This study evaluated the effectiveness and safety of osimertinib (Tagrisso) as first-line therapy for older patients above 75 years with epidermal growth factor receptor (EGFR)-mutated non-small-cell lung cancer (NSCLC). The data showed that osimertinib as first-line therapy is effective in these patients. However, osimertinib was...

Comparing the effectiveness of immune-based combination therapies as first-line treatment for advanced non-small cell lung cancer.

Posted by Medivizor on Dec 31, 2021 in Lung cancer | 0 comments

In a nutshell This study compared the effectiveness of immune-based combination therapies as first-line treatment for advanced non-small-cell lung cancer (NSCLC). The data showed that immunotherapies plus chemotherapy combination was the best treatment for improving overall survival whereas, immunotherapy plus anti-angiogenic therapy plus chemotherapy...

Comparing the effectiveness of epirubicin and cyclophosphamide plus taxanes versus carboplatin plus taxanes in early-stage triple‑negative breast cancer.

Posted by Medivizor on Dec 5, 2021 in Breast cancer | 0 comments

In a nutshell This study compared the effectiveness of epirubicin (Ellence) and cyclophosphamide (Cytoxan) plus paclitaxel (Taxol)/docetaxel (Taxotere) (taxanes) (ECT) versus carboplatin (Paraplatin) plus taxanes (TP) regimens in patients with early-stage triple-negative breast cancer (TNBC). The data showed that both treatment regimens showed...

Evaluating the effectiveness of extended robot-assisted prostate surgery and extended pelvic lymph node dissection in patients with very high-risk prostate cancer.

Posted by Medivizor on Oct 31, 2021 in Prostate cancer | 0 comments

In a nutshell This study analyzed the effectiveness of extended robotic-assisted laparoscopic prostatectomy (eRALP) with extended pelvic lymph node dissection (ePLND) without any other additional treatments for patients with very-high-risk localized prostate cancer (PCa). The study found that eRALP with ePLND alone was safe and effective...

Evaluating the safety and effectiveness of trastuzumab deruxtecan in HER2-mutant non–small-cell lung cancer.

Posted by Medivizor on Oct 24, 2021 in Lung cancer | 0 comments

In a nutshell This study evaluated the effectiveness and safety of trastuzumab deruxtecan (Enhertu) in patients with previously untreated metastatic HER2-mutant non-small-cell lung cancer (NSCLC). The data showed that trastuzumab deruxtecan was safe and showed strong anticancer activity in these patients. Some background NSCLC is the most common form...

Evaluating short-course radiation therapy followed by chemotherapy for patients with rectal cancer.

Posted by Medivizor on Oct 9, 2021 in Colorectal cancer | 0 comments

In a nutshell This study evaluated short-course radiation therapy (RT) followed by chemotherapy as a non-surgical treatment of patients with rectal cancer (RC). The data showed that treatment with short-course RT and chemotherapy is safe and effective for these patients. Some background Colorectal cancer (CRC) is one of the most common types of...

Evaluating the effectiveness and safety of SOX+bevacizumab or cetuximab for the treatment of patients with advanced colorectal cancer with wild-type KRAS.

Posted by Medivizor on Sep 26, 2021 in Colorectal cancer | 0 comments

In a nutshell This study compared the effectiveness and safety of S-1 (tegafur/gimeracil/oteracil) and oxaliplatin (Eloxatin) combined with bevacizumab (Avastin) or with cetuximab (Erbitux) in patients with previously untreated advanced colorectal cancer with wild-type KRAS. This study concluded that the safety and effectiveness of...

Can robot-assisted prostate surgery improve lower urinary tract symptoms and quality of life in patients with prostate cancer?

Posted by Medivizor on Sep 19, 2021 in Prostate cancer | 0 comments

In a nutshell This study assessed whether robot-assisted radical prostatectomy (RARP) improves lower urinary tract symptoms (LUTS) and quality of life (QoL) in patients with prostate cancer (PCa). The data showed an improvement in LUTS and QoL in patients with previously moderate or severe LUTS, 12 months after RARP. Some background PCa...

Comparing platinum-based chemotherapy and immunotherapy for the treatment of patients with early-stage triple negative breast cancer.

Posted by Medivizor on Sep 12, 2021 in Breast cancer | 0 comments

In a nutshell This study compared the effectiveness and safety outcomes of platinum-based chemotherapy and immune checkpoint inhibitors (ICIs) for the treatment of patients with early-stage triple-negative breast cancer (TNBC). The data showed that ICI plus chemotherapy was associated with good outcomes with reduced side effects compared with...

Current disease status-First occurrence of the cancer Posts on Medivizor

Evaluating the effect of total neoadjuvant therapy versus standard neoadjuvant chemoradiotherapy and planned adjuvant chemotherapy on the survival of patients with locally advanced rectal cancer.

Adding pembrolizumab before and after surgery for early triple-negative breast cancer

Is chemotherapy after surgery followed by atezolizumab a good treatment option in patients with early stage non-small-cell lung cancer?

Can osimertinib be used as first-line therapy in older patients with EGFR-mutated NSCLC?

Comparing the effectiveness of immune-based combination therapies as first-line treatment for advanced non-small cell lung cancer.

Comparing the effectiveness of epirubicin and cyclophosphamide plus taxanes versus carboplatin plus taxanes in early-stage triple‑negative breast cancer.

Evaluating the effectiveness of extended robot-assisted prostate surgery and extended pelvic lymph node dissection in patients with very high-risk prostate cancer.

Evaluating the safety and effectiveness of trastuzumab deruxtecan in HER2-mutant non–small-cell lung cancer.

Evaluating short-course radiation therapy followed by chemotherapy for patients with rectal cancer.

Evaluating the effectiveness and safety of SOX+bevacizumab or cetuximab for the treatment of patients with advanced colorectal cancer with wild-type KRAS.

Can robot-assisted prostate surgery improve lower urinary tract symptoms and quality of life in patients with prostate cancer?

Comparing platinum-based chemotherapy and immunotherapy for the treatment of patients with early-stage triple negative breast cancer.

Categories

Recent Posts

Archives

Current disease status-First occurrence of the cancer Posts on Medivizor

Categories

Recent Posts

Archives

Thanks for your interest in Medivizor

Invalid email